Established heart valve companies are putting out second and third generation devices, while start-ups are developing novel technologies to overcome the drawbacks associated with mechanical and tissue valves. The replacement valve market is essentially flat; future growth will come from macro factors such as an aging population or improving economies in third world countries, but companies continue to improve products to retain or capture market share from each other. Meanwhile, start-ups see a new market opening up for percutaneous technologies. Such technologies promise to offer a solution for patients who aren't candidates for surgery. Early intervention could also delay the need for valve replacement procedures. While new heart valves aren't readily adopted by conservative surgeons that already have a host of options that are proven to be safe, interventional cardiologists are eager for the new procedures that the percutaneous technologies promise.
by Mary Stuart
Like any mechanical system, the heart is only as strong as its weakest component. The heart is capable of beating...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.
Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
